Impurity Prediction
Keeping Impurities in Check for a Smoother Drug Development Process
In drug development, spotting and classifying potential impurities early can make all the difference, but traditional methods rely on slow, manual analysis, costing chemists valuable time.
To accelerate research and streamline production, ChemAIRS®' AI-driven impurity prediction provides a faster, more reliable alternative.
How ChemAIRS Supports Impurity Prediction
AI-Powered Impurity Identification
ChemAIRS analyzes chemical reactions at a level comparable to an expert chemist, predicting impurity structures with over 90% accuracy. This ensures early detection, reducing the need for extensive trial-and-error analysis.
Rapid Structural Elucidation
Using AI algorithms, ChemAIRS identifies impurity structures and formation pathways within minutes, significantly improving research efficiency. What previously required hours or even days of manual work can now be done in record time.
Impurity Prediction, Tested Against Published Data
5/6
Known impurities predicted in Fostemsavir C-N coupling
6+1
All known + 1 novel safety signal in Vismodegib nitro reduction
100%
Score across both validated case studies
In two published pharmaceutical syntheses, ChemAIRS identified 5 of 6 known impurities in a Fostemsavir C-N coupling and captured all 6 in a Vismodegib nitro reduction across two condition regimes.
CASE STUDY
Nitro Reduction
Vismodegib
Hedgehog pathway inhibitor — impurity profile shifts entirely with reaction conditions across 2 regimes
ChemAIRS Predicted - Conditions - Aware
Hydroxylamine (incomplete reduction)
Azo byproduct (dimer condensation)
Hydrazine (N-N coupling byproduct)
Des-chloro amine (over-reduction)
C-N Coupling
Fostemsavir
HIV-1 attachment inhibitor - 6 impurities found only after extensive lab condition screening
ChemAIRS Predicted - Before Any Reaction
Triazole regioisomers (N-2 and N-4)
Hydrolysis products (des-benzoyl, C7-OH)
DMCHDA ligand adduct
C-7 hydroxide displacement
It also flagged an additional nitroso compound with potential nitrosamine precursor liability that the published literature had missed. In today's regulatory environment, where nitrosamine risk is under intense FDA and EMA scrutiny, that kind of proactive coverage is the difference between walking into a regulator's conversation prepared and being caught off guard.
Real-World Application in Impurity Studies
ChemAIRS' predictive capabilities were tested against literature data on the tachykinin receptor antagonist TKA731, where impurity formation during BOC group deprotection was analyzed.
Traditionally, resolving these impurities required purification and extensive characterization, such as NMR spectroscopy. With ChemAIRS, the formation routes and impurity structures were predicted within minutes, dramatically reducing research time.